|Type/Class of Therapy||Generic/Trade/|
|Indication||Approving Regulatory Agency|
|Approval was granted to this novel formulation of isotretinoin for the treatment of severe recalcitrant nodular acne. It offers a precise, consistent, and uniform dosage delivery with an absorption characteristic that is stable with or without food when compared with traditional generic isotretinoin.||Health Canada|
|Anesthetic||Lidocaine 7% + tetracaine 7% cream|
Nuvo Research Inc.
|Approval was granted to this topical local anesthetic cream indicated for use on intact skin in adults to provide local analgesia for superficial aesthetic procedures, such as dermal filler injection, pulsed dye laser therapy, facial laser resurfacing, and laser-assisted tattoo removal.||Health Canada|
|Dupuytren’s Contracture||Collagenase clostridium histolyticum|
|Approval was granted to this novel, first-inclass biologic for the treatment of Dupuytren’s contracture in adults with a palpable cord. The injected enzymes dissolve and weaken the contracted collagen cord. It is the only nonsurgical option for Dupuytren’s disease.||Health Canada|
|Hereditary Angioedema||C1 esterase inhibitor (human)|
|This highly purified, pasteurized and nanofiltered plasma-derived C1 esterase inhibitor product was approved for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema.||Health Canada|
|This human monoclonal antibody was approved for the treatment of metastatic melanoma. Administered intravenously, the drug blocks a T-lymphocyte antigen (CTLA-4), altering the body’s ability to fight off cancerous cells and allowing the immune system to recognize, target, and attack cells in melanoma tumors.||Health Canada|
Plexxikon/Daiichi Sankyo Group
|Approval was granted to this oral, small molecule, kinase inhibitor for the treatment of metastatic or unresectable melanoma. Therapy is specifically indicated for patients with BRAFV600E mutationpositive melanoma. This BRAF enzyme inhibitor was approved with a companion diagnostic called the cobas® 4800 BRAF V600 Mutation Test, which determines a patient’s eligibility for treatment.||European Commission|
Skin Therapy Letter uses reasonable efforts to include accurate and up-to-date information, we make no warranties or representations as to the accuracy, completeness, timeliness or reliability of the content and assume no liability or responsibility for any error or omission in the content.